biopharmaassetlistforbio2017-15may

UK Partnering Assets BIO Convention June 2017 San Diego, CA To connect with any of the companies listed here, please contact:

kathryne.kirk@mobile.trade.gov.uk or torrey.ah-tye@mobile.trade.gov.uk

2

2017 Partnering Assets

Contents Antibiotics

3

Autoimmune, Inflammatory and Orphan Disease

5

Cancer: Cancer Research Technology

7

Cancer: General Oncology

9

Cancer: Immune Oncology

13

Cardiovascular, Respiratory and Metabolic Disease

17

Drug Delivery

19

Genetics, Genomics and Gene Therapy

21

Infectious Disease and Virology

23

Central Nervous System

25

Regenerative Medicine, Medical Devices and Software

26

Multiple Therapeutic Areas

28

Diagnostics

31

3

2017 Partnering Assets

ANTIBIOTICS Name MDR ANTIBIOTICS CONTACT: DR DAVID WILLIAMS, CHIEF EXECUTIVE OFFICER

www.discuva.com/ SMALL MOLECULES FOR INFLAMMATION AND ALSO EPIGENETICS CONTACT: DR TOM MANDER, COO

www.domainex.co.uk/ ANTIBIOTICS CONTACT: ADAM STOTEN, HEAD OF TECH TRANSFER - LIFE SCIENCES

https://innovation.ox.ac.uk/ C. DIFFICILE AND MRSA ANTIBIOTICS CONTACT: DR MIRSOLAV RAVIC, CEO

www.mgb-biopharma.com/

About

Assets

Keywords: antibiotics, multi-drug Different novel development resistance, UTI, respiratory infection, stage assets for Neisseria prosthetic joint infections, sepsis, gonorrhea & Gram positive STDs infections.

Description: Development-stage Discovery pipeline of multiple company focused on producing unnamed Gram-negative and new, safe antibiotics effective Gram-positive novel against multidrug-resistant compound series, in chemical bacteria. Highly innovative optimization. discovery platform allowing discovery, refinement and clinical candidate selection of novel antibiotics.

Keywords: TBK1/IKKe, lysine methyltransferases, Combinatorial Domain Hunting Description: Domainex is a drug discovery service company based in Cambridge UK providing protein expression, assay development and screening, hit generation (fragment/virtual screening), and integrated medicinal chemistry incorporating in vitro pharmacology, in vivo DMPK, computational design and synthetic/analytical chemistry.

1. Pre-clinical candidate targeting the kinases TBK1/IKKe for Lupus, COPD and RA. 2. Lysine methyltransferase assets against EZH2, G9a, SMYD2 and SMYD3.

3. Unlock challenging targets via Combinatorial Domain Hunting, a patented high throughput gene fragmentation/protein expression platform.

Keywords: MRSA, infectious endocarditis, SSSI Description: Oxford University Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world.

Keywords: antibiotics, Clostridium difficile, CDAD Description: A clinical-stage company developing a novel class of compounds that targets Clostridium difficile-associated diarrhea (CDAD), and various preclinical stage compounds targeting multi-drug resistant bacterial and fungal infections.

1. First-in-class antibiotic that provides a clear commercial advantage and is supported by novel chemistry and a data package, based on a two-year SAR program.

1. MGB-BP-3, oral for C. diff, Phase II, seeking partners 2. MGB-BP-3, IV for MRSA, VRE, and streptococcus, preclinical 3. MGB-BP-3, topical, pre-clinical Various discovery - stage compounds for Gramnegative bacteria, antifungals, anti-virals and antiparasitics

4

2017 Partnering Assets

ANTIBIOTICS CONT. Name MDR ANTIBIOTICS CONTACT: DR GRAHAM LUMSDEN, CEO

https://www.motifbio.com/ DUCHENNE MUSCULAR DYSTROPHY AND C. DIFFICILE CONTACT: DR ANDREW MULVANEY, VP BUSINESS DEVELOPMENT & ALLIANCE MANAGEMENT

About Keywords: antibiotics, infectious disease, multi-drug resistant bacteria, MRSA, dihydrofolate reductase inhibitor Description: Phase 3 clinical-stage company focused on the development of antibiotics to treat multi-drug resistant bacteria.

Keywords: antibiotics, orphan diseases, Duchenne Muscular Dystrophy, Clostridium difficile Infection Description: Clinical-stage drug discovery and development company focusing on Duchenne muscular dystrophy and C. difficile infection.

Assets 1. Iclaprim, novel antibiotic targeting serious and lifethreatening Gram-positive hospital infections, incl.

ABSSSI, HABP/VABP. Data from two Phase III trials in 2017. FDA/EMA submissions in 2018.

QIDP designation granted.

2. MTF-001, oral and i/v targeting osteomyelitis and PJI, pre-clinical 1. Ridinilazole (SMT19969), a first-in-class, oral selective antibiotic for C. difficile infection, demonstrated superiority over vancomycin on sustained clinical response in Phase II CoDiFy POC trial. Progressing into Phase III. Global rights available under Summit IPRs.

www.summitplc.com/ NATURAL PRODUCT INSPIRED ANTIMICROBIALS CONTACT: DR JOHN NORMANTON, CHIEF EXECUTIVE OFFICER

www.polypharmakos.com/ ANTIBIOTICS – NEONATAL CONTACT: DR SUSAN CONROY, CHIEF EXECUTIVE OFFICER

https://www.therakind.com/

Keywords: Antibacterials, natural products, plants, fungi, insects, 1.

AMR, novel mechanisms of action.

Description: A new natural product screening and drug development company from the University of Cambridge and the Royal Botanic Gardens, Kew focused on the discovery of novel mechanism of action antimicrobial agents.

Keywords: pediatric, neonate, PIP, vancomycin, reformulation, sepsis Description: Therakind is a private UK based pharmaceutical company with the primary objective of increasing the availability of authorized specialty medicines.

Intelligent screening of natural products from major collections worldwide of natural products with particular emphasis on the identification and rapid characterization of new antibacterial hits specifically operating through novel mechanisms of action.

1. Age appropriate parenteral formulation of vancomycin for neonates and infants aged under 3 months with sepsis caused by Staphylococci and nonpyogenic streptococci.

5

2017 Partnering Assets

AUTOIMMUNE, INFLAMMATORY AND ORPHAN DISEASE Name SMALL MOLECULE DRUG DISCOVERY ENGINE CONTACT: DR CRAIG FOX, CHIEF SCIENTIFIC OFFICER

https://www.c4xdiscovery.com/ CHRONIC INFLAMMATORY DISEASES CONTACT: DR NEIL WILKIE, DIRECTOR & CHIEF OPERATING OFFICER

About Keywords: Inflammatory diseases, Diabetes, Cancer, Addiction, 3D ligand conformation, novel target identification, Conformetrix, Taxonomy3, Molplex, small molecules, drug discovery.

Description: C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting its cutting-edge technologies Taxonomy3, Molplex and Conformetrix to design.

Keywords: Phosphodiesterase; cAMP; Autosomal Dominant Polycystic Kidney Disease; ADPKD; Kidney disease; Inflammatory disease; Psoriasis, Chronic Obstructive Pulmonary Disease; COPD; Immuno-oncology; Prostate cancer; Orphan diseases; Rare diseases Description: Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins.

www.mironid.com/ CCR9 ANTAGONISTS CONTACT: DR NEIL FISH, DIRECTOR OF BUSINESS DEVELOPMENT

Keywords: inflammation, preclinical, inflammatory bowel disease, chemokine receptor, gastrointestinal

www.norgine.com/

Description: Leading independent European “go to” specialist pharmaceutical company that has been established for over 100 years and has a presence in all major European markets.

SMALL MOLECULE ORPHAN DRUG CONTACT: BOB BOYLE, CEO

www.sentineloncology.com/

Keywords: rare disease, orphan indication, drug candidate, Fragile X syndrome Description: Drug discovery company dedicated to the development of novel drug candidates in areas of high unmet medical need.

Assets 1. Orexin-1 Antagonist for addictive disorders, Nrf-2 activator for inflammatory diseases including COPD, Small molecule anti-IL-17 inhibitor, Small molecule GLP-1 agonist for diabetes, GPR142 agonist for diabetes.

1. LoAc® program of first in class PDE4 activating compounds for the treatment of rare/ orphan diseases driven by elevated cAMP levels, including ADPKD. 2. ShoLo® program of next generation PDE4 inhibitors with a novel mode of action that selectively inhibits PDE4 short isoforms, and avoids the side effects induced by pan-PDE4 inhibitors, for the treatment of inflammatory diseases, such as psoriasis, psoriatic arthritis and COPD

1. A number of patent protected CCR9 antagonists at the preclinical stage of development that are available for divestment.

1. SOL784 a candidate drug in development for the treatment of Fragile X Syndrome a rare disease and the largest single genetic cause of autism.

6

2017 Partnering Assets

AUTOIMMUNE, INFLAMMATORY AND ORPHAN DISEASE CONT. Name CROHN’S DISEASE CONTACT: DR JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

About Keywords: Methylation, epigenetics, Crohn’s disease, inflammatory bowel disease epigenetic signature Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent medical research charity committed to innovation in multiple fields.

Assets Epigenetic markers for the diagnosis of Crohn’s disease. An epigenetic test based on a blood sample provides a diagnosis of Crohn’s disease in both pediatric and adult patients.

www.mrctechnology.org/ INFLAMMATORY RESPIRATORY DISEASES CONTACT: DR. PAUL CLEWLOW, SVP BUSINESS DEVELOPMENT

www.sygnaturediscovery.com/ DUCHENNE MUSCULAR DYSTROPHY AND C. DIFFICILE CONTACT: DR ANDREW MULVANEY, VP BUSINESS DEVELOPMENT

www.summitplc.com/ MULTI-DISEASE CONTACT: DR ROMAIN LALANDES, BD & LICENSING DIRECTOR

www.vernalis.com/ JYLAMVO – METHOTREXATE REFORMULATION DR SUSAN CONROY, CHIEF EXECUTIVE OFFICER

https://www.therakind.com/

Keywords: Hit identification, hit-to-lead, lead optimization, drug candidate, library design and synthesis, fragment-based drug discovery, computational chemistry, medicinal chemistry, in-vitro biology, DMPK and protein crystallography.

Description: Integrated drug discovery company operating a fully-enabled research facility and scientific staff (80% with PhDs) with all the professional skills to accelerate drug discovery programs into development.

Keywords: antibiotics, orphan diseases, Duchenne Muscular Dystrophy, Clostridium difficile Description: Clinical-stage drug discovery and development company focusing on Duchenne muscular dystrophy and C. difficile infection.

Keywords: drug discovery, small molecules, fragments, structure-based drug discovery, oncology, immunology, inflammation, anti-infectives, Description: Development-stage company focused on products in the therapeutic areas of cough/ cold, CNS, oncology, and inflammation.

Keywords: pediatric, orphan, geriatric, drug delivery, cytotoxic, oral liquid, oncology, chemotherapy, immunology, reformulation Description: Therakind is a private UK based pharmaceutical company with the primary objective of increasing the availability of authorised speciality medicines.

1. Since 2011, have delivered 9 drug candidates (Phases I and II).

2. Integrated drug discovery capability all under one roof (Nottingham, UK).

3. Co-location of medicinal chemistry, computational chemistry, biology and DMPK in the same laboratories to facilitate project success.

4. New £30M HQ and research facility (April 2017).

1. Utrophin Modulator Programme – Disease-modifying therapies for Duchenne Muscular Dystrophy: Lead compound ezutromid (SMT C1100) progressed into the PhaseOutDMD open label POC trial

1. V158866, for pain, spasticity and other neuro, Phase II 2. Research collaboration opportunities to apply drug discovery platform to targets from partners

Jylamvo - oral liquid formulation of methotrexate for use in in adults and children aged over 3 years as a treatment for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriasis (adults only) and for the maintenance treatment of acute lymphoblastic leukaemia. EU Marketing Authorization granted March 2017. Several territories available for licensing.

7

2017 Partnering Assets

CANCER: CANCER RESEARCH TECHNOLOGY Name SMALL MOLECULES OPPORTUNITIES

www.cancertechnology.co.uk/ BIOLOGICAL THERAPEUTICS OPPORTUNITIES

www.cancertechnology.co.uk/

ENABLING TECHNOLOGY OPPORTUNITIES

www.cancertechnology.co.uk/ MEDICAL DEVICES OPPORTUNITIES

www.cancertechnology.co.uk/ DIAGNOSTICS OPPORTUNITIES

www.cancertechnology.co.uk/

About Keywords: enzyme / checkpoint inhibitors, oncology targets, cancer targets, pre-clinical, drug discovery platforms, stem cells Description: Part of Cancer Research UK, CRT develops and commercializes new discoveries in cancer research as ‘the meeting point between academia and industry’.

Assets 1. Chk2 inhibitor program 2. First in class IKK alpha selective inhibitors 3. Inhibitors of autotoxin 4. Novel dual inhibitors of FLT3 & Aurora Kinases

Keywords: antibodies, tumor targeting 1. CEA antibodies peptides, trap therapy, angiogenesis, T-cell 2. vß6-binding peptides for tumor targeting receptors 3.MUC1 Description: Part of Cancer Research 4. S100A4 neutralizing antibody UK, CRT develops and commercializes 5. IGF2-Trap therapy new discoveries in cancer research as 6. vß6 antagonistic antibodies ‘the meeting point between academia and 7. TACE antibody industry’.

8. p53 TCR mimic antibody 9. CLEC14a 10. Jagged1 Monoclonal Antibody 11. LMP2-TCR 12. CXCL12 13. CCR4 14. Anti-CD55 Antibodies Keywords: imaging agents, prostate cancer, glioma, tumor detection, 1. Optimam mammography image radiolabelling, FRET- FILM, leukaemia cell database and viewing software assay, kinase substrate identification Description: Part of Cancer Research UK, 2. Imaging agent for prostate and glioma tumor detection CRT develops and commercializes new discoveries in cancer research as ‘the 3. RALA meeting point between academia and industry’.

Keywords: biological fluid filtration, cancer diagnostics, high intensity focused ultrasound, sonic ablation

1. Biological fluid filtration device, for capture of material from biological fluids, such as tumor cells from urine, patent pending.

Description: Part of Cancer Research UK, CRT develops and commercializes new discoveries in cancer research as ‘the meeting point between academia and industry’.

Keywords: diagnostics, screening, breast cancer risk, imaging validation, ovarian cancer predictive, lung cancer, pancreatic cancer, prostate cancer Description: Part of Cancer Research UK, CRT develops and commercializes new discoveries in cancer research as ‘the meeting point between academia and industry’.

1. vß6 binding peptides for imaging 2. MCM Lung

8

2017 Partnering Assets

CANCER: GENERAL ONCOLOGY Name BICYCLIC PEPTIDES CONTACT: KEVIN LEE, CEO

About

Assets

Keywords: bicyclic peptides, oncology, research collaboration, drug discovery

1. BT1718 bicyclic oncologic agent (pre-clinical)

Description: R&D stage company backed by Atlas Ventures and Novartis Venture funding, among others, exploring the therapeutic possibilities of bicyclic peptides.

2. Research collaboration opportunities to apply proprietary platform to targets from partners

www.bicycletherapeutics.com/ CANCER: OTHER OPPORTUNITIES

www.cancertechnology.co.uk/ ONCOLOGY & WOMEN’S HEALTH CONTACT: DR JOHN NORMANTON, CHIEF EXECUTIVE OFFICER

www.estryxpharma.com SMALL MOLECULE THERAPEUTICS CONTACT: DR. TOBY RICHARDSON, ASSOCIATE DIRECTOR, BUSINESS DEVELOPMENT

www.icr.ac.uk/

Keywords: diagnostics, screening, breast cancer risk, imaging validation, ovarian cancer predictive, lung cancer, pancreatic cancer, prostate cancer

1. IBIS Software (Tyrer-Cuzick Model) 2. S100A4 neutralizing antibody for inflammatory diseases

Description: Part of Cancer Research UK, CRT develops and commercializes new discoveries in cancer research as ‘themeeting point between academia and industry’.

Keywords: oncology, women’s health, hormone-dependent cancer, Dual Aromatase-Sulfatase Inhibitor, steroid sulfatase inhibition, multi-targeting therapeutic, orally-available, hormone replacement therapy, contraception Description: A new drug development company focused on the design and development of small molecule therapeutics in oncology and women’s health.

1. STX140, an orally active, multitargeting, orally- available therapeutic for multiple oncology indications, acting as an irreversible steroid sulfatase inhibitor (STSi); a carbonic anhydrase IX (CAIX) inhibitor; a microtubule disruptor; and an angiogenesis inhibitor.

2. Orally active Dual AromataseSulfatase Inhibitor (DASI) for estrogen- dependent tumors 3. DnE2MATE for oral contraception & HRT

Keywords: novel small molecule inhibitors, enzyme inhibitors, folate receptor, phase 1, hypoxic tumors, AML, colorectal cancer, metastasis, invasion, lung cancer, hepatoma, head and neck tumors, breast cancer, ovarian cancer, colorectal cancer.

Description: A University of London and Royal Marsden hospital affiliated research charity which ranks in the Top 4 institutes for cancer research worldwide.

1. BTG945 (ONX-0801, BGC945): First-in-class α-folate receptor targeted ovarian cancer therapeutic and companion diagnostic; phase I results presented at ASCO 2017 (Abstract #2503).

2. FLT3/AURORA: potent and orally bioavailable clinic-ready dual FLT3/Aurora kinase inhibitor for AML (clinic-ready).

3. LOX: for the treatment of breast, ovarian and colorectal cancer, inhibitors should prevent tumor progression and metastases (late lead optimization).

4. GDEPT: Gene-directed enzyme pro- drug therapy, for treatment of lung, colorectal, head and neck tumors, as well as hepatoma (preclinical).

10

2017 Partnering Assets

CANCER: GENERAL ONCOLOGY CONT. Name ONCOLOGY, CNS & RARE DISEASES CONTACT: EDOARDO NEGRONI, CEO

www.inorgen.com/ CANCER: GENERAL ONCOLOGY CONTACT: ADAM STOTEN, HEAD OF TECHNOLOGY TRANSFER - LIFE SCIENCES

https://innovation.ox.ac.uk/ CANCER: GENERAL ONCOLOGY CONTACT: ADAM STOTEN, HEAD OF TECHNOLOGY TRANSFER - LIFE SCIENCES

About

Assets

Keywords: Oncology, CNS, Rare 1. Immune-oncology platform based on the secretome in Diseases, Alzheimer disease, selected solid tumors checkpoint inhibitors, immunotherapy, late stage cancer 2. anticancer platform combining biomimetic molecules with Description: Drug discovery innovative cytotoxic payloads in engine in Europe focused on the development of early stage assets late stage cancers from academic and non-academic assets into therapeutic opportunities with a solid proof of 3. drug repurposing in a panel of pediatric rare diseases concept ready for industrial partnering

Keywords: biomarker, Ewings sarcoma, oncology Description: Isis Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world.

Keywords: Therapeutic, STSi, CAIX, microtubule, angiogenesis Description: Isis Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world.

1. A novel and specific biomarker on the cell surface of Ewing’s Sarcoma tumors that can be used as a diagnostic or therapeutic target.

1. STX140 - an orally active multi-targeting drug for multiple oncology indications, acting as an irreversible steroid sulfatase inhibitor (STSi); a carbonic anhydrase IX (CAIX) inhibitor; a microtubule disruptor; and an angiogenesis inhibitor.

https://innovation.ox.ac.uk/ CANCER: GENERAL ONCOLOGY CONTACT: ADAM STOTEN, HEAD OF TECHNOLOGY TRANSFER - LIFE SCIENCES

https://innovation.ox.ac.uk/

Keywords: aromatase, 17ß-estradiol, DASI Description: Isis Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world.

1. Orally active Dual AromataseSulfatase inhibitors (DASI) for treatment of estrogen-dependent cancers.

11

2017 Partnering Assets

CANCER: GENERAL ONCOLOGY CONT. Name ONCOLOGY CONTACT: DR JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

About Keywords: immuno-oncology, immunology, oncology, antibodies, neoplasm, signaling molecule modulator, Millipore kinase panel, autophagy Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent medical research charity committed to innovation in multiple fields.

Assets 1. MNK Inhibitors for outlicensing 2. ULK Inhibitors for outlicensing 3. PAICS Inhibitors for outlicensing

www.mrctechnology.org/ CANCER DIAGNOSTICS CONTACT: DR JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

Keywords: cancer, oncology, kidney, renal cell carcinoma, tyrosine kinase inhibitors, diagnostic, gene profile, sunitinib, response

www.mrctechnology.org/

Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent medical research charity committed to innovation in multiple fields.

ONCOLOGY THERAPEUTICS CONTACT: DR JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

Keywords: cancer, oncology, therapeutic, pro-drug, therapeutic, palladium activated, endotoxaemia, ang2, angiopoietin, sepsis retinopathy, Src, abl, breast cancer, ovarian cancer

Genetic markers for therapy in renal cell carcinoma (RCC) Provides stratification of renal cell carcinoma to improve patient outcome and therapy options.

1. Targeting cancer therapeutics with palladium-activated compounds 2. Ang2 specific biotherapeutic 3. Specific Src inhibitor

www.mrctechnology.org/ T-CELL THERAPIES CONTACT: HELEN TAYTON-MARTIN, CHIEF BUSINESS OFFICER

adaptimmune.com

Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent medical research charity committed to innovation in multiple fields.

Keywords: T-cell therapy, Peptide Engineering, Immune System, TCR Therapies

1. T-cell therapy targeting NY-ESO peptide across multiple cancer types, Phase 1/2 trials

Description: Pre-clinical company focused on proprietary SPEAR (Specific Peptide Engineered Affinity Receptor) T-cell engineering platform.

2. MAGE-A10 T-cell therapy 3. AFP TCR therapeutic targeted to a peptide associated with hepatocellular carcinoma 4. MAGE-A4 TCR SPEAR T-cell therapy

12

2017 Partnering Assets

CANCER: GENERAL ONCOLOGY CONT. Name ONCOLOGY CONTACT: DR ANDY MORLEY, CHIEF SCIENTIFIC OFFICER

About Keywords: oncology, Glioblastoma, research collaboration, drug discovery, small molecule, brain penetrant

Assets 1. Proprietary novel approach for the treatment of Glioblastoma Multiforme and other cancer indications. Pre-clinical.

Description: Opal Oncology seek out commercially viable anti cancer therapies in high-impact orphan cancer indications which have been failed by existing therapies.

www.opalonc.com/ NOVEL DRUG TARGETS IN ONCOLOGY CONTACT: CHRIS TORRANCE, CHIEF EXECUTIVE OFFICER

www.phoremost.com/ ORPHAN ONCOLOGY CONTACT: JEFFREY EISENBERG, CHIEF OPERATING OFFICER

www.xeneticbio.com/ ONCOLOGY & AUTOIMMUNE DISEASES CONTACT: DR TIM MITCHELL, CHIEF EXECUTIVE OFFICER

www.sareum.com/

Keywords: Phenotypic drug discovery, PROTEIN-interference technology, first-in-class targets, collaborative R&D, outlicensing portfolio

1. R&D collaborations Pre-clinical stage asset for oncology (AML and mutant KRAS cancers).

Description: PhoreMost is using a proprietary druggable target identification platform called ‘Protein Interference’ (PROTEINi®) to systematically provide first-in-class drug discovery programs for outlicensing to Pharma.

Keywords: orphan drugs, oncology, endometrial cancer, triple negative breast cancer, TNBC, sodium cridanimod, anemia, erythropoietin, EPO, PSA-EPO, PolyXen™.

Description: Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics.

1. Sodium cridanimod in Phase II for endometrial cancer and preclinical stage for triple negative breast cancer.

2. Polysialylated EPO, in Phase II for anemia in pre-dialysis CKD patients.

Keywords: oncology, lung cancer, pancreatic cancer, AML, lymphoma, neuroblastoma, JAK family, psoriasis, rheumatoid arthritis, RA, multiple sclerosis, MS, lupus, inflammatory bowel disease, IBD

1. Aurora+FLT3 kinases inhibitor, targeting AML and ALL (preclinical)

Description: Drug discovery and development company, with a focus on targeted small molecule therapeutics for cancer and autoimmune diseases.

3. TYK2 inhibitor program targeting psoriasis, rheumatoid arthritis, inflammatory bowel disease, lupus and other autoimmune diseases

2. TYK2 kinase inhibitor, targeting T-ALL (lead opt)

13

2017 Partnering Assets

CANCER: IMMUNE ONCOLOGY Name ANTIBODY THERAPEUTICS CONTACT: DANIEL BARTON, DIRECTOR, INVESTOR RELATIONS

www.biosceptre.com/ MULTISPECIFIC ANTIBODIES: KAR-T™ AND ICHECK™ TRIBODY™ AGENTS CONTACT: DR PEDRO DE NORONHA PISSARRA, CHIEF EXECUTIVE OFFICER

About Keywords: basal cell carcinoma, nfP2X7, monoclonal (domain) antibody, peptide vaccine colorectal, breast, prostate, lung, cancer, solid tumor, oncology, cancer, immuno-oncology Description: Biosceptre is UK based biotech with three pro ducts in the clinical pipeline, all targeting a novel on cology target - nfP2X7, a form of P2X7 that is expressed only in the tumour microenvironment, and which occurs in a broad range of cancers

www.f-star.com/ FUSION ANTIBODIES CONTACT: DR PAUL KERR, MANAGING DIRECTOR

https://www.fusionantibodies.com/

1. BIL03s is our systemic monoclonal (domain) antibody – for solid tumors - entering Phase 1 in Q3 2017 2. BIL06v is our peptide vaccine for solid tumors entering Phase 1 in Q3 2017 3. BIL010t is our topical Antibody treatment for locally advanced Basal Cell Carcinoma (laBCC) - Phase 2 in Q3 2017

Keywords: basal cell carcinoma, nfP2X7, monoclonal (domain) antibody, peptide vaccine

1. Tb535, pan-cancer Tcell engager for 5T4 expressing tumors, preclinical

Description: Immuno-oncology company developing multispecific T-cell engagers and immunemodulators which locally counter potential blocking signals on T and NK cells.

2. Tb434, pan-cancer T-cell engager against Triple Negative Breast Cancer, preclinical

www.biotecnol.com/ BISPECIFIC ANTIBODIES CONTACT: DR JANE DANCER, CHIEF BUSINESS OFFICER

Asse ts

Keywords: bispecific antibodies, immuno-oncology, Modular Antibody Technology™, Fcab™, mAb²™, cytokines Description: Clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer.

3. Tb232, novel anti-HER2 T-cell engager for mutated and resistant metastatic breast cancers, pre-clinical 4. Various early-stage programs 1. Bispecific antibody programmes in immunooncology 2. Modular Antibody Technology platform for strategic collaborations on bispecific antibodies and Fcbased formats

1. Fsn0503h, an antiCathepsin S antibody, against colorectal, breast, prostate, glioblastoma and other cancers (pre- clinical as monotherapy and in Description: Antibody humanization combination) company with a preclinical-stage pipeline of antibodies through its 2. Fsn1006 dual specific Fusion Therapeutics division.

IgG1 monoclonal antibody which binds AREG and HB-EGF, against colon, breast, lung and other cancers (pre-clinical) Keywords: immuno-oncology, monoclonal antibodies, colorectal cancer, breast cancer, lung cancer, prostate cancer, glioblastoma

14

2017 Partnering Assets

CANCER: IMMUNE ONCOLOGY CONT. Name T CELL RECEPTOR-BASED THERAPIES CONTACT: EVA-LOTTA ALLAN, CBO

www.immunocore.com/ ANTIBODY THERAPEUTICS OPPORTUNITIES CONTACT: DR. TOBY RICHARDSON, ASSOCIATE DIRECTOR, BUSINESS DEVELOPMENT

www.icr.ac.uk/ CANCER: IMMUNE ONCOLOGY CONTACT: STEPHEN SHUTTLEWORTH, CHIEF SCIENTIFIC OFFICER

www.karustherapeutics.com/

MONOCLONAL ANTIBODIES CONTACT: DR STEVE DOWD, DIRECTOR, BUSINESS DEVELOPMENT

kymab.com/

About Keywords: ImmTAC, T cell receptor, immunology, oncology, HLA targets, malignant cutaneous melanoma, ocular melanoma, glioblastoma Description: Clinical-stage company focused on innovative therapies called ImmTACs, based on its proprietary T cell receptor technology.

Keywords: rat monoclonal antibodies, Her2, Neu, EGFR, Cerb-B2.

Description: A University of London and Royal Marsden hospital affiliated research charity which ranks in the Top 4 institutes for cancer research worldwide.

Keywords: Cancer, Targeted Therapy, Cancer Immunotherapy, Tumor Microenvironment, TME, Small Molecule, Treg Cell, MDSC, Immunomodulator, Immune Checkpoint, B-cell Lymphoma, PI3K, PI3 Kinase, HDAC6, p110b, p110d, Solid Tumor, Epithelial Tumor, PD-L1 Description: Clinic stage biopharma company developing oral small molecules for the treatment of solid tumors and haematological cancer. These molecules are in clinical trials at the MD Anderson Cancer Center in Houston, Texas.

Keywords: monoclonal antibodies, immunology, oncology, drug discovery, mouse models, anemia, chronic pain, dyslipidemia, infectious diseases, Ebola Description: Preclinical- stage company focusing on development of monoclonal antibody drugs in immuno- oncology, immunology, and opportunistic spaces.

Assets 1. IMCgp100, completed Phase II for malignant cutaneous and ocular melanoma 2. Additional Assets undisclosed, pre-clinical

1. 1. Monoclonal antibodies against EGFR, thorough preclinical characterization for all, one has completed Phase 1B trials.

2. Monoclonal antibodies against Cerb-B2, extensive preclinical evaluation completed.

1. KA2237 is a first-in-class dualPI3K-p110β/δ inhibitor with broad potential to treat hematological and solid tumors, including aggressive β/δ expressing Non-Hodgkin Lymphomas such as Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma, as well as ibrutinib resistant blood cancers.

2. KA2507 is a highly-selective, oral, small molecule HDAC6 inhibitor that has potential in the treatment of liquid tumors such as multiple myeloma and lymphoma, and PD-L1-expressing tumors such as melanoma by acting as a cancer immunotherapeutic.

1. KY1005, Anti-OX40L, for immunology 2. KY1006, Anti-LIGHT, for immunology 3. Numerous other discovery-stage assets for oncology, anemia, chronic pain, Ebola and others

15

2017 Partnering Assets

CANCER: IMMUNE ONCOLOGY CONT. Name ANTI-GLYCAN THERAPEUTIC MONOCLONAL ANTIBODIES CONTACT: DR TINA PARSONS, MANAGER

www.nottingham.ac.uk/nutac/ ONCOLYTIC IMMUNOTHERAPIES CONTACT: JOHN BEADLE, CHIEF EXECUTIVE OFFICER

psioxus.com/ ONCOLOGY, FIBROSIS & AUTOIMMUNE DISEASES CONTACT: NICHOLAS ADAMS, CHIEF BUSINESS OFFICER

redxpharma.com/ MONOCLONAL ANTIBODY THERAPEUTICS CONTACT: DR SALMAN RAHMAN, CEO

vasgen.co.uk

About Keywords: immunotherapy, monoclonal antibodies, oncology, solid cancers, pre- clinical, immunogenic cell death, bispecific antibodies, ADC, CAR-T Description: NUTAC develops therapeutic monoclonal antibodies to tumor associated glycans.

Keywords: immuno-oncology, oncology, cancer, checkpoint, antibody, oncolytic, oncolytic virus, T-cell, gene therapy, cytokine, delivery, shRNA, immunology Description: Clinical stage Oxford based company focused on immuno-oncology. Oncolytic viruses and cancer specific immuno-gene-therapy.

Keywords: small molecules, oncology, immune-oncology, tumors, cancer inhibitors, fibrosis, IPF, kidney fibrosis, diabetic nephropathy, antibacterial, multidrug resistant bacteria, autoimmune Description: Engaged in the discovery and development of novel small molecule therapeutics targeting high unmet needs in oncology, fibrotic and autoimmune diseases.

Keywords: ADAMs, ADAM15, Metzincin, AMD, cancer, AbIMP, metalloprotease, antiangiogenesis Description: Pre-clinical-stage company developing first-in- class monoclonal antibody therapies for unmet needs in ophthalmology and oncology medicine.

Assets 1. FG129 pre-clinical monoclonal antibody, recognizes a Sialyl-diLewisa 2. FG88 pre-clinical monoclonal antibody, recognizes Lewisa,c,x 3. FG27 pre-clinical monoclonal antibody 4. Platform and additional early stage pre-clinical assets available for licensing

1. Enadenotucirev a systemically available oncolytic virus currently in combination studies with both checkpoint and chemotherapeutic agents 2. NG-347: directs tumor cells to produce membrane bound CD80 and secrete interferon alpha and MIP1 alpha 3. NG-350: directs tumor cells to secrete a full length antibody (mAb identity currently undisclosed) 4. NG-600 series: direct tumor cells to secrete BITes directed against stromal targets such as fibroblasts 1. Porcupine antagonists – preclinical development (oncology & fibrosis) 2. BTK reversible inhibitors – preclinical development (oncology & autoimmune) 3. Pan-RAF antagonists – lead optimization (oncology) 4. MDR gram negative infections – lead optimization

1. First-in-class monoclonal antibody therapy for neovascular age-related macular degeneration: pre-clinical.

2. AbIMP® platform: Targetenabling antibody platform for selective inhibition of intractable metzincin proteases: proof-ofconcept

16

2017 Partnering Assets

CARDIOVASCULAR, RESPIRATORY AND METABOLIC DISEASE Name CARDIOVASCULAR, RESPIRATORY AND METABOLIC DISEASE CONTACT: ADAM STOTEN, HEAD OF TECHNOLOGY TRANSFER - LIFE SCIENCES

About Keywords: miR-31, atrial fibrillation, nNOS

Keywords: vascular disease, stroke, kidney transplant, heart disease, prenatal diseases, oncology, skin cancer, diabetes, obesity, metabolic disease

magnuslifescience.co.uk

Description: Preclinicalstage company with multiple development programs based on five technologies with differing foci, each with a lead scientist from UCL.

CARDIOVASCULAR AND RESPIRATORY OPPORTUNITIES CONTACT: DR JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

Keywords: heart attack (MI), tuberculosis (TB), diagnostic antibodies, protein, peptide, pulmonary fibrosis, type-2 immune response, humanized antibody, inflammatory response

www.mrctechnology.org/ SEVERE HYPOGLYCAEMIA CONTACT: DR SUSAN CONROY, CHIEF EXECUTIVE OFFICER

https://www.therakind.com/

1. miR-31 as a specific target for regulating atrial fibrillation.

Description: Isis Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around the world.

https://innovation.ox.ac.uk/ MULTI-DISEASE CONTACT: DR DAVID CAMPBELL, CHIEF EXECUTIVE OFFICER

Assets

Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent medical research charity committed to innovation in multiple fields.

Keywords: drug delivery, severe hypoglycaemia, diabetes, intranasal device, reformulation Description: Therakind is a private UK based pharmaceutical company with the primary objective of increasing the availability of authorized speciality medicines.

1. ‘Oxygen’ for STEMI, stroke and kidney transplant (preclinical) 2. ‘Metabolic’ for type II diabetes and obesity (pre-clinical) 3.‘Life’ for melanoma and solid tumors (pre-clinical) 4. ‘Growth’ for placental insufficiency, pre- eclampsia and pre-term labor (preclinical)

Cardiovascular 1. Myocardial Infarction; small molecule for cardioprotection following ischemia-reperfusion injury during heart attack Respiratory 1. IL17BR humanized antibody

Undisclosed nasal powder for severe hypoglycaemia

17

2017 Partnering Assets

CARDIOVASCULAR, RESPIRATORY AND METABOLIC DISEASE Name AIRWAYS DISEASES CONTACT: DR PETER HIRST, VP, BUSINESS DEVELOPMENT

About Keywords: airways disease, respiratory, formulation, inhalation, asthma, COPD, inflammatory, PAH, cystic fibrosis, RSV Description: Develops inhalation products for respiratory diseases. 7 inhaled, 4 non-inhaled and 10 oral products marketed by partners. Outlicense agreements for a portfolio of drugs in clinical development.

www.vectura.com/

Assets DPI device technologies GyroHaler®, Lever-operated, Openinhale-close, Unit-dose pMDI device technologies flutiform® Smart nebuliser delivery systems AKITA® JET, FOX® Formulation technologies A range of formulation technologies for inhaled small and large molecules for pMDI and DPI dosage forms.

LIVER THERAPIES CONTACT: DANIEL GREEN, CHIEF EXECUTIVE OFFICER

yaqrit.com/

Keywords: Liver disease, cirrhosis, ACLF, NASH, NAFLD, ALF, alcoholic cirrhosis.

Description: Yaqrit has two programs entering Phase II clinical trials in 2017.

Two of them are supported by EU Horizon 2020 grants worth a total of €12.3 million.

For details of Yaqrit’s product development programs, please contact Daniel Green, CEO, at daniel.green@yaqrit.com

18

2017 Partnering Assets

DRUG DELIVERY Name RESPIRATORY DELIVERY AND CONSUMABLES CONTACT: STEVEN KAUFMAN, GLOBAL BD LEAD

About Keywords: drug delivery, respiratory, inhalers, injectables, device manufacturing, device licensing Description: A Consort Medical company and a leading global supplier of drug delivery devices for injectable and inhaled products, with a focus on the respiratory market.

www.bespak.com/ DEVELOPING PATIENTCENTRIC DRUG DELIVERY CONTACT: JAMES OTTER, CHIEF EXECUTIVE OFFICER

glide-technologies.com/

Assets 1. Syrina, range of injectors from assisted syringes to autoinjectors, VapourSoft technology, for out-licensing 2. Lapas, market-ready bolus injection device with VapourSoft technology, disposable, for outlicensing 3. Lila, pre-filled syringe technology which allows twodrug mixing, for out-licensing

1. Glide SDI速 (Solid Dose Injector) Keywords: self-administration, peptides, injectables, solid dose, vaccines, influenza, anthrax, needle-free, patient-centric, osteoporosis, acromegaly

2. Octreotide SDI速 successful phase I clinical study 2016.

3. Teriparatide SDI速, phase I in H2 2017

Description: Clinical-stage company developing easily administered, needle-free, therapeutics and vaccines using solid dose formulation and proprietary injection device.

4. Exenatide SDI速, proof-of concept PK H2 2015

Keywords: nanotech, gold nanoparticles, rare cancers, diabetes, neurology, ophthalmology, glioblastoma, brain cancer, ovarian cancer, liver cancer, pancreatic cancer

1. GNP Insulin, Phase II

Description: Clinical-stage nanomedicine company focused on the development of multiple, highvalue, targeted therapies for diseases with unmet medical need.

4. For glioblastoma, pre-clinical

5. Anthrax vaccine, partnered with Pfenex Inc, preclinical

1.

DELIVERY VIA GOLD NANOPARTICLES (GNPS) CONTACT: DR TIM SPAREY, CHIEF BUSINESS OFFICER

www.mrctechnology.org/

3. GLP-1 / Insulin combination, pre-clinical

5. Q-Ocreotide, pre-clinical 6. For ovarian cancer, med chem.

7. For liver cancer, med chem

www.midatechpharma.com/ CELL PENETRATING PEPTIDES CONTACT: DR JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

2. GLP-1 / Q-Exenatide, Phase I

Keywords: cell-penetrating, peptide, therapeutic, delivery Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent charity committed to preclinical-stage innovation in multiple fields.

1. Cell penetrating peptides with demonstrated efficacy in transporting biological molecules into cells and improving disease outcome in vivo.

20

2017 Partnering Assets

DRUG DELIVERY CONT. Name MET NANOPARTICLES CONTACT: ANDREAS SCHATZLEIN, CHIEF EXECUTIVE OFFICER

About Keywords: acute/chronic neuropathic pain, ocular therapy, ophthalmology, fungal infections, leishmaniasis Description: Nanomerics’ Molecular Envelope Technology (MET) delivers a step change in target-site availability of drugs and biological APIs across epithelial barriers.

Assets 1. NM-0147: Oral therapy of systemic fungal infections (505(b)2) 2. NM-0127: Fast treatment of acute and chronic pain

www.nanomerics.com/ INTRANASAL DRUG DELIVERY DEVICE CONTACT: DR SUSAN CONROY, CHIEF EXECUTIVE OFFICER

Keywords: drug delivery, intranasal device, reformulation Description: Therakind is a private UK based pharmaceutical company with the primary objective of increasing the availability of authorized speciality medicines.

Undisclosed, novel, reusable, intranasal dry powder drug delivery device, pre-clinical and clinical

https://www.therakind.com/ BIOLOGIC DRUG DELIVERY CONTACT: JEFFREY EISENBERG, CHIEF OPERATING OFFICER

Keywords: biologics, anemia, predialysis, CKD, erythropoietin, EPO, polysialic acid, polysialylation, PSA, PSA-EPO, PolyXen™.

Description: Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics.

1. Polysialylated EPO, in Phase II for anemia in pre-dialysis CKD patients.

2. PolyXen™, a patented platform technology for creating proprietary, next-generation protein and peptide therapeutics.

www.xeneticbio.com/ NANOSCALE INJECTION CONTACT: DR LAURA LANE, BUSINESS DEVELOPMENT MANAGER

Keywords: Technology transfer, Anti-infectives, Antivirals, Women’s Heath, Oncology, Cancer, Drug Discovery Platforms, Biologics Delivery Platform, Diabetes, Cryopreservation Description: The University of Warwick’s (UK), Technology Development and Commercialization Office

www2.warwick.ac.uk/service s/ventures/

Protein-based nanoscale injection platform for the cellspecific delivery of biologics Other opportunities can be found here: http://www2.warwick.ac.uk/servic es/ventures/licensing/licensingopportunities/

21

2017 Partnering Assets

GENETICS, GENOMICS AND GENE THERAPY Name GENE-BASED MEDICINE CONTACT: PETER NOLAN, CHIEF BUSINESS OFFICER

www.oxfordbiomedica.co.uk/ LipTideTM – a new, custombuilt vector to deliver your gene therapy CONTACT: DR ALAN WALKER, DIRECTOR BUSINESS DEVELOPMENT

www.LipTide.com

RNA-BASED THERAPEUTICS CONTACT: LUCIO IANNONE, RESEARCH & DEVELOPMENT MANAGER

About Keywords: gene therapy, cell therapy, lentiviral vectors, ophthalmology, Parkinson’s disease, oncology, cancer vaccines, CAR-T, bioprocessing /manufacturing.

Description: Clinical-stage company focused on the development of gene and cell therapies for ophthalmic, CNS, and oncologic diseases. World class bioprocessing facilities for GMP production of lentiviral vectors.

https://www.congenica.com/

1. Integrated LentiVector® platform for gene delivery 2. OXB-102 for Parkinson’s disease, Phase I/II ready 3. OXB-202 for corneal graft rejection, Phase I/IIa ready 4. OXB-301 cancer vaccine for solid tumors Phase II 5. OXB-302 (CAR-T 5T4) for cancer, pre-clinical

Keywords: gene therapy, siRNA, gene

1. LipTideTM can be modified to

editing, DNA, RNA vaccine, delivery, viral, liptide, liposome, crispr, CAS9, saRNA, mRNA, DNA, plasmid

target different cell types and does not accumulate in the liver.

2. LipTideTM has been

Description: The greatest challenge facing researchers has been the inability to deliver nucleic acids into target cells with efficiency, specificity and minimal side effects and this is holding back the true potential of gene therapy. Nanogenics is proud to introduce LipTideTM; an exciting custom-built delivery vehicle for all gene therapy. Every aspect of LipTideTM can be modified to target different cell types and deliver different payloads. Nanogenics are looking to out-licence LipTideTM to help translate your gene therapy into potential clinical programs.

successfully administered in vivo by nebulisation, systemic delivery (i.v.) and by convectionenhanced delivery to the brain.

3. LipTideTM delivers for all nucleic acid payloads including siRNA, saRNA, mRNA, DNA and even artificial chromosomes.

1. Atu027, against pancreatic cancer, Phase II Keywords: genetic medicine, pancreatic cancer, head and neck cancer, lung disease, pulmonary hypertension, RNA interference, 2. Atu027, against head and neck gene silencing, messenger RNA, RNAi, mRNA cancer, Phase I Description: Clinical-stage company which utilizes RNA interference (RNAi) and mRNA technology to develop therapies which ‘silence’ disease-causing gene expression.

3. Atu111, against lung indications, pre-clinical 4. Unnamed, against pulmonary hypertension, discovery-stage 5. Pre-clinical micro RNA and messenger RNA programs

www.silencetherapeutics.com/ DECODING GENETIC DISEASES CONTACT: TOM WEAVER, CEO

Assets

Keywords: Clinical Genomics, Rare Disease Diagnosis, Genome Interpretation, Next Generation Sequencing, NGS, WES, WGS, Genomic Software, Genome Analysis, Exome Analysis, Genetic Variant Interpretation Software.

Description: Congenica is a global company founded on pioneering research from the Wellcome Trust Sanger Institute. We’ve translated this research into the gold standard clinical genomic analytics platform, Sapientia.

Congenica has developed Sapientia, a platform that integrates a suite of analytical tools enabling rapid and accurate interpretation of a patient’s genotype and phenotype data to facilitate a faster and more accurate diagnosis.

22

2017 Partnering Assets

GENETICS, GENOMICS AND GENE THERAPY CONT. Name CELL & GENE THERAPY CONTACT: DR DAVID VENABLES, CHIEF EXECUTIVE OFFICER

www.synpromics.com/ CELL & GENE THERAPY CONTACT: DR TOMMY DUNCAN, GROUP BUSINESS DEVELOPMENT OFFICER

About Keywords: Gene therapy, cell therapy, gene editing, oncolytic viruses, biopharmaceutical production, synthetic promoters.

Description: Synpromics is a synthetic biology company with IP and know-how in the design of synthetic promoters. Our synthetic promoters enable the controlled expression of genes at a specific place, in a specific environment, at a specific time, or in response to a specific biological condition.

Keywords: DNA, gene therapy, cell therapy, mRNA, monoclonal antibodies, cancer vaccine, prophylactic vaccine, DNA vaccine; AAV, lentivirus, CRISPR Description: Touchlight has developed the enzymatic means of DNA amplification that can truly enable the commercialization of DNA-based therapeutics.

www.touchlight.com/ GENE SILENCING CONTACT: MARK TREHARNE, CORPORATE DEVELOPMENT MANAGER

www.valirx.com/

Keywords: genetic medicine, oncology, GeneICE, Bcl-2 inhibition, prostate cancer, breast cancer, ovarian cancer, endometriosis, cancer screening, lung cancer Description: Clinical-stage company developing cancer therapies and associated biomarkers, with sub-focuses in neurology and inflammatory disease.

Assets 1. So far synthetic promoters targeting liver, lung, keratinocytes, dendritic cells, muscle and the eye have been created 2. We have a panel of CHO and yeast specific promoters for enhanced biopharmaceutical production 3. We create novel synthetic promoters according to custom requirements 1. Cell and gene therapy: Touchlight is developing AAV and lentiviral gene therapy candidates in-house and is licensing its technology to leaders developing products in the field.

2. Touchlight has also evidenced its technology in DNA vaccines, mRNA, mAb and gene-editing applications.

1. VAL 101 GeneICE Bcl-2 inhibitor, against prostate, ovarian, and pancreatic cancers 2. VAL 201, against prostate cancer (with potential in breast and ovarian cancers, endometriosis), Phase I 3. VAL 401, against lung cancer, pre-clinical

23

2017 Partnering Assets

INFECTIOUS DISEASE AND VIROLOGY Name VIRUS-LIKE PARTICLE VACCINES CONTACT: DR ALEX RAMIREZ, LEAD IMMUNOLOGIST

www.iqur.com/ INFECTIOUS DISEASE, VIROLOGY CONTACT: ADAM STOTEN, HEAD OF TECHNOLOGY TRANSFER - LIFE SCIENCES

About Keywords: vaccines, virology, infectious disease, virus-like particles, influenza, malaria, hepatitis, burkholderia, FMDV, CMV, cancer, Tandem Core™, Diagnostics, Liver Fibrosis Test, Clinical Stage Description: Preclinical- stage company focused on the development of a broad spectrum of vaccines delivered as proprietary virus-like particles (VLPs).

Keywords: DENV proteins, dengue fever, vaccine Description: Isis Innovation is a wholly-owned subsidiary of the University of Oxford, managing technology transfer and academic consulting for Oxford, and providing consultancy services to clients around

Assets Vaccines for...

1. Influenza, pre-clinical 2. Malaria, pre-clinical 3. Hepatitis, pre-clinical 4. FMDV, pre-clinical 5. CMV, pre-clinical 6. Cancers, discovery and development stage 7. Influenza virus A point of care rapid diagnostic, pre-clinical

1. Dengue fever vaccine designed to generate full protection against all DENV serotypes.

https://innovation.ox.ac.uk/ INFECTIOUS DISEASE OPPORTUNITIES CONTACT: DR JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

Keywords: vaccines, diagnostics, mouse models, new class of antivirals, HIV-1, asthma, ulcerative colitis (UC), tuberculosis (TB) Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent medical research charity committed to innovation in multiple fields.

1. Tuberculosis; rapid ex vivo diagnostic 2. HIV-1; a universal HIV-1 vaccine called HIVcon 3. Asthma and Ulcerative Colitis; antibody against IL-25 and type 2 immune responses, humanized 4. Junbo, a mouse model with OM for antibiotic research

www.mrctechnology.org/ ANTI-INFECTIVES CONTACT: DR DEBORAH O’NEIL, CHIEF EXECUTIVE OFFICER

www.novabiotics.co.uk/

Keywords: anti-infectives, antibacterial and antifungal therapies, MDR infections, Gram-negative bacterial infections cystic fibrosis, onychomycosis, aspergillosis Description: NovaBiotics is a leading AMR focused, clinical- stage company developing antibacterial and antifungal therapies from its novel AMR focused technology platforms that have been engineered from components of the innate immune response to infection.

1. NovaBiotics has three advanced product candidates in clinical development (Lynovex, Novexatin, Luminaderm) for difficult to treat bacterial and fungal infections, plus; 2. Earlier stage compounds for MDR bacterial Gram negative infections, MRSA, aspergillosis, candidemia, cryptococcosis 3. Therapeutic candidates have been developed from two novel AMR focused platforms based on innate immune antimicrobial peptides and cysteamine

24

2017 Partnering Assets

INFECTIOUS DISEASE AND VIROLOGY CONT. Name RSV CONTACT: DR EDDY LITTLER, CHIEF EXECUTIVE OFFICER

www.reviral.co.uk/ INFECTIOUS DISEASE OPPORTUNITIES CONTACT: DR LAURA LANE, COO

www.virionhealth.com/ ANTI-INFECTIVES CONTACT: DR LAURA LANE, BD MANAGER

About Keywords: antiviral, RSV, respiratory syncytial virus

1. An RSV fusion inhibitor RV521 recently completed a successful Phase 1 clinical trial

Description: ReViral is a leading 2. RSVrep, for RSV, in pre-clinical development antiviral company progressing a best-in-class inhibitor of RSV. The Company has recently completed a Phase 1 clinical trial with excellent exposure and no significant adverse events

Keywords: Single Dose, Respiratory, Biological Antiviral, broad spectrum, intranasal, respiratory viral infections, Influenza, RSV. Description: VirionHealth is a spinout company from the University of Warwick with a disruptive therapeutic platform targeting a wide range of respiratory diseases

Keywords: Technology transfer, Anti-infectives, Antivirals, Women’s Heath, Oncology, Cancer, Drug Discovery Platforms, Biologics Delivery Platform, Diabetes, Cryopreservation Description: The University of Warwick’s (UK), Technology Development and Commercialization Office

www2.warwick.ac.uk/

Assets

1. VH224 is a non-infectious derivative of influenza A virus that has two antiviral modes of action: 2. Inhibits replication of infectious influenza A viruses 3. Stimulates local (innate) Interferon (type I) induction and is therefore active against interferon-sensitive viruses.

1.

Anti-RSV DDX3 Inhibitor

2.

Natural Product Discovery Platform producing compounds active against a range of bacterial pathogens. Including those that have shown promising and specific activity against the Gram-negative, multidrug-resistant bacterium Acinetobacter baumannii,

3.

GLO-1 Inducer for Diabetic Kidney Disease

4.

Anti-infective (gram +ve and gram –ve) Metallohelices Anti-cancer Metallohelices

5.

6.

Cyro-preservation compounds and methodologies for cells, blood and proteins Other opportunities can be found here: http://www2.warwick.ac.uk/services/ventures/lic ensing/licensing-opportunities/

25

2017 Partnering Assets

CENTRAL NERVOUS SYSTEM Name HEARING DISORDERS CONTACT: CARINA SANTOS, TRANSLATIONAL RESEARCH MANAGER

www.actiononhearingloss.org.uk/ HEARING DISORDERS CONTACT: DR BARBARA DOMAYNE-HAYMAN, CHIEF BUSINESS OFFICER

About Keywords: age-related hearing loss (presbycusis), noise-induced hearing loss, ototoxicity, hearing disorders, deafness, tinnitus Description: As the largest not-for-profit organization representing people with hearing loss and tinnitus in the UK, we work globally with companies, academics, and investors to accelerate the development of therapeutics to treat hearing loss and tinnitus.

Keywords: hearing loss, schizophrenia, Fragile X Description: Clinical stage company focused on therapeutics for CNS disorders, including schizophrenia, Fragile X and hearing disorders

Assets 1. Translational hearing research funding 2. Hearing disorders therapy area expertise 3. Market intelligence 4. Connections to key opinion leaders 5. Access to people with hearing loss and tinnitus to aid recruitment into clinical trials

1. AUT00063, in Phase IIa for improvement in speech-in-noise and hearing tests for users of cochlear implants 2. AUT00206, for schizophrenia, Phase Ib studies ongoing

www.autifonytherapeutics.com/ NEURODEGENERATIVE DISEASES THERAPEUTICS & DIAGNOSTICS CONTACT: DR JOHN NORMANTON, CHIEF EXECUTIVE OFFICER

www.swanseainnovations.com/co mpanies/cholestenix.html

Keywords: neurodegenerative disease, cholesterol metabolites, oxysterols, cholestenoic acids, motor neuron disease, ALS, Parkinson’s disease, Alzheimer’s disease, therapeutics, LC-MS/MS diagnostics and biomarkers, Description: A new drug and diagnostic development company focused on the roles of cholesterol metabolites, oxysterols and bile acids in the brain in neurodegenerative diseases.

1. CHX100-xD, a site-specific deuterated cholestenoic acid for treatment of motor neuron disease/ ALS 2. Discovery therapeutic projects on the role of other cholesterol metabolites in Alzheimer’s, Parkinson’s and breast cancer.

3. Quantitative LC-MS/MS diagnostics/ biomarkers for ALS and several orphan diseases

26

2017 Partnering Assets

CENTRAL NERVOUS SYSTEM CONT. Name DEGENERATIVE AND BEHAVIORAL BRAIN DISEASE, AGEING CONTACT: DR HUW JONES, CHIEF EXECUTIVE OFFICER

About Keywords: ALS, MS, eating disorders, addictive behaviors, Huntington’s and Parkinson’s disease, FTD and Alzheimer’s disease, age-related diseases, cellular chronological lifespan regulation, anti-aging

www.chronostherapeutics.com PSYCHIATRIC, BEHAVIORAL AND CNS THERAPEUTICS CONTACT: RUSS PENDLETON, MANAGING DIRECTOR

Keywords: addiction, aggression, anxiety, bipolar disease, CNS, depression, epilepsy, insomnia, pain, Parkinson’s disease, psychosis, sexual dysfunction, Tourette’s Description: Formuli is a licensing agency that also develops its own products, mainly 505b2 and hybrid approval products.

formuli.eu/business-development/

CONTACT: DR SUSAN CONROY, CHIEF EXECUTIVE OFFICER

https://www.therakind.com/

1. RDC5, for ALS approaching Phase II ready 2. DAT Inhibitor in MS fatigue orexin-1 antagonist in addictive behaviors 3. TrkB activator in PTSD

Description: Clinical-stage company focused on the development of NCEs and repositioned FDA/ EMA approved drugs in degenerative and behavioral diseases of the CNS.

SEDATION – PEDIATRIC

Assets

Keywords: pediatric, PIP, clonidine, reformulation, PICU Description: Therakind is a private UK based pharmaceutical company with the primary objective of increasing the availability of authorized speciality medicines.

4. ChronoscreenTM, a proprietary disease model and lifespan screening platform

1. Potent Anti-depressant with libido enhancement for Ex US territories. Clinicals complete, dossier to be prepared and submitted for Europe.

2. Long Acting Tablet Aripiprazole for Once Weekly Oral dosing – sold for China, in late stage negotiations for South America and Europe. Available for US with strong Patent protection.

3. Potent anti-inflammatory for IBD, Asthma & Uveitis. Excellent preclinical data, clinic-ready.

4. Transdermal invisible spray-on patch, PoC data in ADHD, also available for Parkinson’s, Alzheimer’s, Migraine, Epilepsy and other conditions.

1. Age appropriate parenteral formulation of clonidine for use in sedation of children (birth to 18 years) in the pediatric intensive care unit.

27

2017 Partnering Assets

REGENERATIVE MEDICINE, DEVICES AND SOFTWARE Name MEDICAL DEVICES OPPORTUNITIES CONTACT: DR. TOBY RICHARDSON, ASSOCIATE DIRECTOR,

About

Assets

Keywords: rapid and accurate slicing of tissue samples, coalignment, tissue imaging, tissue arrays, high sample density, cervix imaging, microscopic imaging, digital imaging, photoacoustic imaging, ultrasound imaging.

1. Device for tissue processing: prototypes sold to academic researchers.

2. Endocovitary coil for improved 3T-MR diagnostic imaging of the cervix (proof of concept, clinical ongoing).

3. Polyscope: solution for visualization of digital microscopic samples (pre- production prototype in development).

Description: A University of London 4. ARF-LOVIT system: for reducing clutter and Royal Marsden hospital in medical photoacoustic, ultrasound and affiliated research charity which other imaging using acoustic radiation ranks in the Top 4 institutes for force-based localised vibration tagging. cancer research worldwide.

BUSINESS DEVELOPMENT SOFTWARE OPPORTUNITIES CONTACT: DR. TOBY RICHARDSON, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT www.icr.ac.uk/

Keywords: MRI, distortion, correction, display, software.

Description: A University of London and Royal Marsden hospital affiliated research charity which ranks in the Top 4 institutes for cancer research worldwide.

CONTACT: DR ROBIN QUIRK, EXECUTIVE DIRECTOR

2. MRI Distortion Correction: Algorithms for evaluation and correction of geometric distortion in MR images, for applications including radiotherapy treatment planning.

3. 4D Orthogonal Display Tool: Software tool for rapid identification of tissue movement artifacts during analysis of dynamic MR .

www.icr.ac.uk/ TISSUE REGENERATION DEVICES

1. 3D Kinetic Volume Rendering Tool for MRI: software to enable separate display of MIPs derived from different phases of MR contrast capable kinetics.

Keywords: tissue regeneration, orthopedic matrices, cell therapy, drug delivery, injectables, tissue scaffolds Description: Preclinical-stage company focused on the development of their proprietary TAOS injectable matrix technology, and several potential applications thereof.

1. TAOS osteoinductive therapeutic for orthopedic bone and joint fusion indications, preclinical 2. TAOS osteoconductive void filler for grafting procedures, pre-clinical 3. RPMax – thermoreversible 3D scaffold for trypsin-free cell expansion 3. IntraStem – high-performance intracellular update agent

www.locatetherapeutics.com/ REGENERATIVE MEDICINE CONTACT: DR YEN CHOO, CHIEF EXECUTIVE OFFICER

www.progenitorlabs.com/

Keywords: regenerative drug, osteoarthritis, multiple sclerosis, Duchenne muscular dystrophy

1. Small molecule drug assets for regeneration of articular cartilage to treat osteoarthritis

2. Program in regeneration of myelin to treat multiple sclerosis Description: Progenitor therapeutics discovers drugs that 3. Program in regeneration of muscle to regenerate specific tissues of treat Duchenne muscular dystrophy the human body in response to 4. Platform technology to discover disease or ageing. regenerative drug targets

28

2017 Partnering Assets

MULTIPLE THERAPEUTIC AREAS Name LONGITUDINAL SERUM SAMPLES FOR BIOMARKER DISCOVERY AND VALIDATION CONTACT: NADIA ALTOMARE, CEO

About Keywords: biomarkers, validation, human serum, cancer, cardiovascular disease, diabetes, population studies Description: Abcodia licenses access to a unique longitudinal serum bio bank that allows biomarkers to be studied within individuals and across a population over time, from healthy to diagnosis and therapy.

Assets Serum bio bank derived from 202,000 initially free from cancer postmenopausal women, 50,000 of whom donated annually for 10 years.

The bank is available for biomarker discovery and validation work and covers every disease such a large population would develop in 15 years.

www.abcodia.com/ TUNEABLE PEPTIDE HYDROGELS CONTACT: ELEANORE IRVINE, BUSINESS DEVELOPMENT MANAGER

biogelx.com/ THERAPY FOR THE TREATMENT OF URGE INCONTINENCE CONTACT: CATHERINE HUNTER, BUSINESS DEVELOPMENT DIRECTOR

www.crystecpharma.com/

DISCOVERY-STAGE CHEMISTRY CONTACT: SIMON BURY, HEAD OF BUSINESS DEVELOPMENT

synmedchem.com/

Keywords: peptide hydrogels, cancer research, toxicology assays, 3D bio-printing, regenerative medicine, drug delivery

1. Biogelx Powder – Hydrogel with tuneable mechanical and chemical properties, optimized for 3D cell culture, bioprinting and drug delivery

Description: Biogelx designs and supplies a family of tunable peptide hydrogels that mimic the behavior of the body’s tissues and organs – creating new opportunities for cell biology applications.

Keywords: urology, genitourinary, women’s health, urge incontinence, anticholinergic, inhaled, particle engineering Description: Crystec applies the latest supercritical fluid (SCF) crystal and particle technology to enable the development of innovative medicines in a range of therapeutic areas including urology, respiratory, women’s health and malaria.

Keywords: heterocyclic chemistry, peptide/cyclic-peptide and peptidomimetic chemistry (solution phase), nucleotide synthesis, natural products chemistry, SP3 carbon chemistry, asymmetric synthetic chemistry, metathesis Description: A discovery-stage chemistry CRO with high-quality, cost effective custom synthesis and medicinal chemistry and project management.

1. CR002 - a fast acting, inhaled therapy for the treatment of urge incontinence.

The concept has strong support from clinicians and patients, as well as encouraging pre-clinical data. Currently seeking a partner to progress the product through clinical trials.

For details of SYNthesis Med Chem’s product development programs, please contact Simon Bury.

29

2017 Partnering Assets

MULTIPLE THERAPEUTIC AREAS, CONT. Name QUANTITATIVE PROTEOMICS & DRUG TARGET IDENTIFICATION CONTACT: DR FRANCESCO RAO, SCIENTIFIC DIRECTOR

About Keywords: proteomics, mass spectrometry, drug discovery Description: DC Biosciences Ltd aims to provide pharmaceutical and biotech companies with proteomics services to support the development of safer drugs faster.

Assets For more information on DC Biosciences’ proteomic platforms, contact Dr. Francesco Rao (Scientific Director).

https://www.dcbiosciences.com MOLECULAR IMAGING CONTACT: IAN WILSON, CEO

www.edinimage.com/ NATURAL PRODUCT LIBRARY CONTACT: FRANK SCHEFFLER, BUSINESS DEVELOPMENT MANAGER

www.hyphadiscovery.co.uk/ BIOTRANSFORMATION PLATFORM CONTACT: FRANK SCHEFFLER, BUSINESS DEVELOPMENT MANAGER

www.hyphadiscovery.co.uk/

Keywords: molecular diagnostics, SMART agents, pharmacokinetic modulator, peptides, small molecules

1. EMI-137 - A phase IIb colorectal cancer (CRC) agent to detect early cancerous lesions in the colon

Description: Developing a unique range of Fluorescent imaging agents that enable real-time molecular imaging of lung disease and cancer during medical interventions.

2. EMI-200 - A phase II ready inflammation agent - with the ability to image activated neutrophils.

Keywords: natural products, screening library Description: Hypha Discovery is a microbial technology company helping partners in pharmaceutical and agrochemical R&D succeed through the discovery and production of microbial and mammalian metabolites.

Keywords: metabolite production, glucuronide synthesis, lead diversification, CH-activation, late-stage functionalization Description: Hypha Discovery is a microbial technology company helping partners in pharmaceutical and agrochemical R&D succeed through the discovery and production of microbial and mammalian metabolites.

1. Entomopathogenic fungi derived fraction library available for screening

1. An efficient platform to produce up to gram amounts of hard to synthesise metabolites and late stage functionalized derivatives of lead compounds for SAR studies and identification of active metabolites.

The platform also allows collaborative diversification of failed clinical assets.

30

2017 Partnering Assets

MULTIPLE THERAPEUTIC AREAS CONT. Name BIOMARKER OPPORTUNITIES CONTACT: DR. TOBY RICHARDSON, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

About Keywords: MPS1, ATR, biomarker, stratification, diagnostic, SMARCB1-deficient, Sarcoma, PDGFRα, FGFR1, resistance.

www.icr.ac.uk/

Description: A University of London and Royal Marsden hospital affiliated research charity which ranks in the Top 4 institutes for cancer research worldwide.

ILLINGWORTH RESEARCH GROUP CONTACT: JOHN ILLINGWORTH, CHIEF EXECUTIVE OFFICER

Keywords: full service CRO, mobile and on-site research nursing, patient centricity, medical photography, respiratory, medical devices, oncology, orphan diseases, dermatology.

illingworthresearch.com/

NOVEL IMAGING BIOMARKERS CONTACT: KEVIN COX, CHIEF EXECUTIVE OFFICER

www.imanova.co.uk/ DEVICE & SOFTWARE OPPORTUNITIES CONTACT: DR. JOHN KELLY, ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT

www.mrctechnology.org/

Description: Multinational clinical CRO offering niche services in research nursing and medical photography. Experience in all trial phases across various therapeutic areas.

Keywords: PET, MRI, pre-clinical imaging, clinical imaging, stratification, analysis, MIAKAT®, CNS, dementia, neurodegeneration, psychiatric, oncology, respiratory, inflammation, biomarkers, radiochemistry Description: Imanova develops novel imaging biomarkers for drug development by providing information on drug/target interactions, dose range for SAD, MAD and PoC studies, and PD response.

Keywords: medical devices, advanced wound healing, regenerative medicine, product packaging, imaging, TEM, OPT, HTS, graphene delivery Description: MRC Technology is the tech transfer arm of the Medical Research Council, an independent charity committed to preclinical-stage innovation in multiple fields.

Assets 1. MPS1 inhibitor Resistance Diagnostic: based on point mutations that confer resistance against multiple inhibitors.

2. ATR Inhibitor Sensitivity Diagnostic; method of identifying cancer patients likely to be responsive to treatment with an ATR inhibitor.

3. Treatment of SMARCB1-deficient Sarcomas: basis for dual targeting with inhibitors towards PDGFRα and FGFR1.

1. A wealth of clinical experience within respiratory, oncology, dermatology and orphan diseases.

2. A patient centric approach to clinical trials with specialist mobile research nurses taking the trial to the patient in addition to on-site research nursing support.

3. Medical photography experience providing equipment provision, image analysis and clinical assessments and advice.

1. Existing imaging biomarkers for a wide range of disease targets including: beta-amyloid, tau, neurodegeneration, psychiatric disorders, oncology 2. Novel biomarkers for fibrosis, inflammation, PDE10, mitochondria and astrocytes 3. MIAKAT™ - comprehensive and easy-to-use molecular imaging analysis software

1. Optical projection tomography (OPT) 3D microscopy 2. Novel graphene support films for biological molecules 3. Flywheel, a platform for live HTS imaging 4. GMCSH-PGE, for wound healing, topical or in dressings 5. Oxygen sensors for packaging (shelf-life monitor)

31

2017 Partnering Assets

DIAGNOSTICS Name IN VITRO DIAGNOSTICS CONTACT: DR DAVID RIBEIRO, CHIEF EXECUTIVE OFFICER

proaxsis.com/ DIAGNOSTIC OPPORTUNITIES CONTACT: WILL DRACUP, CHIFE EXECUTIVE OFFICER

biosignatures.com/ WOMEN’S HEALTH CONTACT: DR LAURA LANE, BUSINESS DEVELOPMENT MANAGER

About Keywords: diagnostics, neutrophil elastase, cystic fibrosis, COPD, bronchiectasis, plasmin, other protease targets

1. ProteaseTag® Active Neutrophil Elastase Immunoassay – registered with European CE mark for use in COPD, bronchiectasis and CF. 2. Neutrophil Elastase point-of-care test Description: ProAxsis is developing a - in late stage development for use in range of products using patented COPD, bronchiectasis and CF; ProteaseTags® commercial partner(s) sought. for the capture, detection and 3. ProteaseTag® Active Plasmin measurement of active protease Immunoassay – in late-stage biomarkers for diseases including development for use in IPF and precystic fibrosis, bronchiectasis and eclampsia COPD. 4. ProteaseTag® Active Tryptase Immunoassay – in late-stage development for use in asthma and COPD Keywords: Diagnostics, prognostics, prostate, bladder, renal, cancer, discover platform, analytics software, machine learning, proteomics.

Description: Diagnostic discovery platform. The first output of this system is a prostate cancer diagnostic marker - a single analyte that in an independently blinded validation trial outperformed competitive offerings.

Keywords: Technology transfer, Anti-infectives, Antivirals, Women’s Heath, Oncology, Cancer, Drug Discovery Platforms, Biologics Delivery Platform, Diabetes, Cryopreservation Description: The University of Warwick’s (UK), Technology Development and Commercialization Office

https://www2.warwick.ac.uk

Assets

1. BiopSave – a clinically validated prostate cancer diagnostic marker.

2. Bladder and renal diagnostic and prostate prognostic markers in clinical development.

3. A proteomics software and clinical research platform that enables the reliable discovery of new protein based diagnostics.

1. New Test to Accurately Determine the Onset of Labour 2. IVF pre-implantation screening method Other opportunities can be found here: http://www2.warwick.ac.uk/services/ve ntures/licensing/licensingopportunities/